Health Care
Medtronic delivered solid FY2026 results with revenue growing 8.4% to $36.4B and operating cash flow rising 4.1% to $7.3B, though net income growth lagged at 3.0% due to higher operating expenses.
关键风险:Elevated SG&A and Cost Structure
SG&A expenses of $11.8B represent a significant cost burden relative to revenue, and cost of revenue growth of 9.4% outpaced revenue growth of 8.4%, compressing gross profit margins. If this trend continues, Medtronic may struggle to expand profitability even as top-line growth continues.
同属 Health Care Equipment 行业的其他公司